SD BIOSENSOR INC.
Financials
Valuation Metrics
SD BIOSENSOR INC.'s Market Cap is ₩8283B. At end of 2025 it was ₩1.1T. Ranked #366 of 2,419 in KR market (top 15%), #244 of 781 on KOSPI (top 31%), #9 of 95 in Health Care Equipment & Services (top 9%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 828.34B KRW | KR#366/2,419 Sec#9/95 |
| Revenue | 738.76B KRW | KR#491/2,419 Sec#4/95 |
| Net Income | -731.09B KRW | KR—/2,419 Sec—/95 |
| Total Assets | 2.90T KRW | KR#245/2,419 Sec#1/95 |
| Net Assets | 2.41T KRW | KR#159/2,419 Sec#1/95 |
| Employees | 613 | KR#408/2,419 Sec#6/95 |
| Value | ||
| P/B | 0.34x | KR#379/2,419 Sec#3/95 |
| P/S | 1.12x | KR#1,402/2,419 Sec#27/95 |
| FCF Yield | 36.27% | KR#122/2,419 Sec#1/95 |
| Profitability | ||
| ROE | -30.39% | KR#2,183/2,419 Sec#78/95 |
| ROA | -25.20% | KR#2,282/2,419 Sec#85/95 |
| Op. Margin | -8.75% | KR#1,963/2,419 Sec#62/95 |
| Revenue Growth | 5.15% | KR#1,189/2,419 Sec#64/95 |
| Earnings Growth | -489.33% | KR#1,299/2,419 Sec#47/95 |
| Financial Health | ||
| Debt Ratio | 20.61% | KR#381/2,419 Sec#21/95 |
| Total Debt | 536.85B KRW | KR#292/2,419 Sec#2/95 |
| FCF | 300.43B KRW | KR#88/2,419 Sec#1/95 |
| Cash | 230.22B KRW | KR#235/2,419 Sec#2/95 |
| Current Ratio | 6.51x | KR#188/2,419 Sec#17/95 |
| Dividend | ||
| Div. Yield | 2.92% | KR#607/2,419 Sec#9/95 |
| Div. Growth | 0.00% | KR—/2,419 Sec—/95 |
| Performance | ||
| 1Y Return | -31.12% | KR#1,782/2,419 Sec#60/95 |
| 1M Return | 11.18% | KR#873/2,419 Sec#47/95 |
| From 52W High | -36.89% | KR#1,062/2,419 Sec#34/95 |
| 1Y MDD | -44.99% | KR#828/2,419 Sec#25/95 |
| Trading | ||
| Volume | 481,692 shares | KR#752/2,419 Sec#27/95 |
| Trading Value | 3.25B KRW | KR#869/2,419 Sec#30/95 |
| Foreign Own. | 5.97% | KR#732/2,419 Sec#22/95 |
| Per Share | ||
| EPS | -6,055 KRW | KR—/2,419 Sec—/95 |
| BPS | 19,924 KRW | KR#539/2,419 Sec#6/95 |
Company Info
SD BIOSENSOR, established in 2010 as a spin-off from SD Co., Ltd.'s biosensor division, is a mid-sized company as of 2024. The company primarily focuses on R&D and sales of in-vitro diagnostics, including immunochemistry, molecular, point-of-care, and self-blood glucose monitoring. SD BIOSENSOR is expanding its global market and portfolio through a network of over 100 exclusive dealers, direct sales in key countries, and quality competitiveness, including WHO PQ approval. Headquartered in Suwon, Gyeonggi-do, it was founded in 2010.